Cagrilintide 5 mg

Cagrilintide Acetate is a next-generation amylin analogue peptide currently under clinical development, designed to support sustained weight loss in individuals with overweight or obesity.
It is being explored both as a standalone therapy and in combination with Semaglutide, a GLP-1 receptor agonist, to deliver enhanced appetite suppression and long-term metabolic benefits.

Mechanism of Action

Amylin is a naturally occurring hormone that is co-secreted with insulin by pancreatic beta cells.
It works by influencing both the homeostatic and hedonic regions of the brain, helping reduce food intake and promote a feeling of fullness (satiety).

When Cagrilintide, an amylin analogue, is combined with Semaglutide (a GLP-1 receptor agonist), their complementary mechanisms produce an additive effect on appetite regulation and energy balance:

• Cagrilintide (Amylin analogue) → Enhances satiety, delays gastric emptying, reduces food cravings.
• Semaglutide (GLP-1 agonist) → Increases insulin release, decreases glucagon secretion, and further slows gastric emptying.

Together, these effects can help improve metabolic efficiency, support long-term weight control, and potentially improve glucose tolerance.

Clinical Insights

Recent clinical trials have shown that Cagrilintide Acetate, both alone and in combination with Semaglutide, can lead to significant and sustained weight reduction.
This combination therapy targets multiple metabolic pathways, providing a more effective pharmacological approach for obesity management.

Given the complexity and multifactorial nature of obesity, therapies that act on different biological targets are increasingly recognized as the most promising strategies for meaningful and lasting weight loss outcomes.

Important Disclaimer

This is a UGL (Underground Laboratory) product. Please be aware that it may not be of pharmaceutical-grade quality. Exercise caution before purchasing or using this product.

Frequently Asked Questions (FAQ)

1. What is Cagrilintide Acetate used for?
Cagrilintide Acetate is an investigational peptide designed to help with weight management and appetite regulation. It mimics the natural hormone amylin, promoting satiety and reducing food intake.

2. Can Cagrilintide Acetate be used with Semaglutide?
Yes. Studies have shown that combining Cagrilintide with Semaglutide may produce stronger weight loss effects than using either compound alone. However, this combination is still under clinical investigation.

3. How is Cagrilintide administered?
Cagrilintide Acetate is typically administered subcutaneously (under the skin), using a sterile vial for injection. The exact dosage and protocol should only be followed under professional supervision.

4. Is Cagrilintide Acetate approved for medical use?
No. As of now, Cagrilintide is still in the research and clinical trial phase. It has not been approved by the FDA or other global regulatory agencies for general medical use.